medigraphic.com
ISSN 1817-5996 (Electronic)

2020, Number 2

<< Back Next >>

Rev Cub de Reu 2020; 22 (2)

Systemic sclerosis and neoplastic purpose of a study at Holguin province

Remedios BSE, Proenza CM, Rodríguez RLG

Language: Spanish
References: 14
Page: 1-10
PDF size: 323.92 Kb.


ABSTRACT

The systemic sclerosis (SS) is a disease of unknown cause, that the fact that they fix the extra-cell womb characterizes itself for a production exaggerated of molecules. The decrease in the production of nitric oxide for the microvasculature’s endothelial cells seems to play a central role in the pathogenesis of the disease. The results attained in 44 patients' study of series of cases of universe and inmunosupresor with cyclophosphamide according to therapeutic applied conduct shows of 31, with low incidence of the causes neoplastic in the death like secondary reactions and to treatment you went from motivation for the presentation of this work, that you reflected the possible relation between the systemic sclerosis and the neoplastic. It was concluded that the relation between auto-immunity and cancer can stem from an etiological common origin (genetic, hormonal, metabolic or environmental factors) or a mechanism of syndrome paraneoplastic. The disease is earthly of risk for neoplastic funny remark, the same way that the neoplastic can induce SS.


REFERENCES

  1. Fériz AR, Louis MR, Espinoza RL, Khamashta M, Cerinic MM, Sanmartí R, et al. Enfermedades inflamatorias reumatológicas. Ed. Producciones científicas Ltda. PANLAR; 2016. p.397-419.

  2. Remedios Batista SE, Montada Cedeño E, del Campo Avilés E, Torres Pérez L, Fernández Portelles A, et. al. Mecanismos etiopatogénicos en la esclerosis sistémica. CCM. 2016 [Acceso 22/06/2016];20(1):[aprox 1 p.]. Disponible en: http://www.revcomed.sld.cu

  3. Remedios Batista SE, Montada Cedeño E, Rivas Carralero R. Caracterización clínica epidemiológica de pacientes con esclerosis sistémica en Holguín. Rev Cub de Reuma. 2018 [Acceso 30/04/2019];20(1). Disponible en: http://www.revreumatologia.sld.cu/

  4. Domsic RT, Dezfulian C, Shoushtari A. Endothelial dysfunction is present only in the microvasculature and microcirculation of early diffuse systemic sclerosis patients. Clin Exp Rheumatol. 2014 [Acceso 30/04/2019];32(Suppl. 86):154-60. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed?

  5. Ingegnoli F, Ughi N, Dinsdale G, Orenti A, Boracchi P, Allanore Y, et al. EULAR Study Groupon Microcirculation in Rheumatic Diseases. Rheumatol. 2017 Nov [Acceso 30/04/2019];37(11):1879-1890. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27469583/

  6. Anaya JM, Shoenfeld Y, Correa Paula A, Carrasco García M, Carrasco RC, et al. Autoinmunidad y enfermedad autoinmune. El Mosaico de la autoinmunidad. Endotelio: órgano blanco en las enfermedades autoinmunes sistémicas. Medellín: Nomos; 2005; 2(11):p.147-54.

  7. Moinzadeh P, Fonseca C, Hellmich M, Shah A, Chighizola C, Denton CP, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Research & Therapy [Internet]. 2014 [Acceso 25/04/2019];16:R-53. Disponible en: https://arthritis-research.biomedcentral.com/track/pdf/10.1186/ar4486

  8. Sakurai K, Otsuka A, Miyachi Y, Kabashima K. Fixed drug eruption induced by Cyclophosphamide. Eur J Dermatol. 2012 [Acceso 23/03/2019];22(3):401-2. Disponible en: http://www.jle.com/medline, md?

  9. Anton JM, Castro P, Espinosa G, Marcos M, Gandia M, Merchan R, et al. Mortality and long term survival prognostic factors of patients with systemic autoimmune diseases admitted to anintensive care unit. Clin Exp Rheumatol. 2012 [Acceso 25/06/2019]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed?

  10. De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Nicole SL. Serum Interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013 [Acceso 30/04/2019];40;435-446. Disponible en: http://www.jrheum.org/content/40/4/435

  11. del Pilar Cruz-Domínguez M, Martínez-Godínez A, Miliar-García A, Itandehui Bautista-Jiménez M, Jandete-Rivera F, Vera-Lastra OL, et al. Grosor íntima-media de las variantes alélicas G894T y T-789C de eNOS en pacientes con esclerosis sistémica. Revista Médica del IMSS. 2015 Jun [Acceso 30/04/2019];(2)53:S46-52. Disponible en: http://search.ebscohost.com/login.aspx?

  12. Graña D, Vargas A, Bèrez A, Goñi M, Danza A. Esclerosis sistémica: forma de presentación y manejo terapéutico. Experiencia de un grupo de trabajo en enfermedades autoinmunes sistémicas. Rev Urug Med Interna. 2018 [Acceso 30/04/2019];1:15-22. Disponible en: http://www.scielo.edu.uy/pdf/rumi/v3n1/2393-6797-rumi-3-01-15.pdf

  13. Santosa A, Tan CS, Teng GG, Fong W, Lim A, et al. Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort. Scandinavian Journal of Rheumatology. 2016 [Acceso 23/06/2017];45(6):[aprox 1]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27469583/

  14. Montoya N, Díaz CJ. Angiosarcoma cutáneo asociado a esclerosis sistémica. Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica. 2016 Abr [Acceso 30/04/2019]; 24(2):122-6. Disponible en: http://search.ebscohost.com/login




2020     |     www.medigraphic.com